Tilray Brands Reports Record Q2 Revenue, Improved Net Loss, and Shifts to Net Cash Position; Reaffirms FY26 Adjusted EBITDA Guidance

summarizeSummary

Tilray Brands reported record Q2 fiscal 2026 net revenue of $218 million, significantly improved its net loss, and moved to a net cash position, while reaffirming its full-year Adjusted EBITDA guidance.

check_boxKey Events

• Record Quarterly Net Revenue

  The company achieved record Q2 fiscal 2026 net revenue of $218 million, representing a 3% increase compared to the prior year period.

• Improved Net Loss

  Net loss improved by $41.8 million to $(43.5) million in the second quarter, compared to a net loss of $(85.3) million in the prior year.

• Shift to Net Cash Position

  Tilray Brands improved its financial position by moving to an overall net cash position of $27.4 million, a $31.2 million sequential improvement from a net debt position.

• Reaffirmed Adjusted EBITDA Guidance

  The company reaffirmed its Adjusted EBITDA outlook for fiscal 2026 at $62 million to $72 million, despite a slight Q2 decline to $8.4 million from $9.0 million year-over-year.

auto_awesomeAnalysis

Tilray Brands' latest earnings report indicates a positive trajectory with record quarterly net revenue and a significant improvement in net loss. The company's shift from a net debt to a net cash position highlights strengthened financial health and increased liquidity, providing flexibility for strategic investments. While overall revenue growth was modest, strong performance in international medical cannabis and the distribution segment, coupled with reaffirmed full-year Adjusted EBITDA guidance, suggests operational stability. The CEO's emphasis on potential opportunities from U.S. federal cannabis rescheduling positions the company for future growth in a key market.